Point of Care Nano-Technology, Inc. (PCNT)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -73.41 Thousand USD | -18.46% |
| 2022 | -61.98 Thousand USD | -726.41% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2015 | -12.95 Thousand USD | -64064.84% |
| 2014 | - USD | -57.09% |
| 2013 | - USD | 21.03% |
| 2012 | - USD | 74.15% |
| 2011 | -577.29 Thousand USD | -171.74% |
| 2010 | -212.44 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 FY | - USD | -18.46% |
| 2023 Q4 | -25.87 Thousand USD | -200.01% |
| 2023 Q3 | -8623.00 USD | 28.17% |
| 2023 Q2 | -12 Thousand USD | -39.21% |
| 2023 Q1 | -8623.00 USD | 28.17% |
| 2022 Q4 | -12 Thousand USD | -105.65% |
| 2022 FY | - USD | -726.41% |
| 2022 Q1 | -42.25 Thousand USD | -463.4% |
| 2022 Q2 | -13.79 Thousand USD | 67.35% |
| 2022 Q3 | -5837.00 USD | 57.69% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q4 | -7500.00 USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2015 Q3 | -118.27 Million USD | -282894.29% |
| 2015 Q2 | -41.79 Thousand USD | 87.68% |
| 2015 Q1 | -339.25 Thousand USD | -1102.57% |
| 2015 FY | - USD | -64064.84% |
| 2015 Q4 | -126.27 Thousand USD | 99.89% |
| 2014 FY | - USD | -57.09% |
| 2014 Q4 | -28.21 Thousand USD | 44.06% |
| 2014 Q2 | -62.27 Thousand USD | -103.47% |
| 2014 Q1 | -30.6 Thousand USD | -28.66% |
| 2014 Q3 | -50.42 Thousand USD | 19.02% |
| 2013 Q1 | -40.03 Thousand USD | -37.89% |
| 2013 FY | - USD | 21.03% |
| 2013 Q3 | -23.4 Thousand USD | 23.54% |
| 2013 Q2 | -30.61 Thousand USD | 23.54% |
| 2013 Q4 | -23.78 Thousand USD | -1.63% |
| 2012 Q3 | -35.19 Thousand USD | 0.52% |
| 2012 Q4 | -29.03 Thousand USD | 17.5% |
| 2012 FY | - USD | 74.15% |
| 2012 Q1 | -49.6 Thousand USD | 18.45% |
| 2012 Q2 | -35.38 Thousand USD | 28.68% |
| 2011 Q1 | -439.84 Thousand USD | 0.0% |
| 2011 Q2 | -23.97 Thousand USD | 94.55% |
| 2011 Q3 | -52.64 Thousand USD | -119.59% |
| 2011 Q4 | -60.82 Thousand USD | -15.54% |
| 2011 FY | - USD | -171.74% |
| 2010 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | 83.587% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 99.751% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 99.936% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 99.534% |
| Better Therapeutics, Inc. | -38.26 Million USD | 99.808% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 99.808% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 99.59% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 99.782% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 99.78% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 99.931% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | 91.963% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 99.774% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 99.843% |
| Innovation1 Biotech Inc. | -5.68 Million USD | 98.708% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 99.55% |
| Molecular Templates, Inc. | 1.43 Million USD | 105.134% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | 99.471% |
| NexImmune, Inc. | -28.16 Million USD | 99.739% |
| Orgenesis Inc. | -60.71 Million USD | 99.879% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 99.857% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 99.545% |
| Scopus BioPharma Inc. | -11.71 Million USD | 99.373% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 99.986% |
| Statera Biopharma, Inc. | 38.93 Million USD | 100.189% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 98.934% |
| Trevena, Inc. | -35.28 Million USD | 99.792% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -30.981% |
| Vaccinex, Inc. | -19.74 Million USD | 99.628% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | 92.988% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 99.843% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 98.989% |